Industry / United Kingdom

GSK Reforms Pricing Structures

March 2008 | Industry News

In what could usher in a paradigm shift in the drug sector, UK-based pharmaceutical giant

To read the full article, please choose one of the following options:

Subcribers please log in

Related Insight Articles

Reckitt Benckiser Focuses On Growth In Emerging Markets

Industry / United Kingdom BMI Core View: Emerging markets will drive industry growth and their importance to multinational drugmakers cannot be overstated. BMI's Pharmaceutical Expenditure Model shows that five-year compound annual...

December 2010

GE Focuses On Personalised Medicines

Industry / United Kingdom BMI View: Multinational drugmakers involvement in theranostics, or the development and marketing of therapeutics in combination with diagnostics, will become more common. It is increasingly clear that...

November 2010

AstraZeneca To Divest Medical Devices Division

Industry / United Kingdom BMI View: Drugmakers targeting a wide range of therapeutic areas and diversifying their product range will significantly enhance their long-term growth opportunities. Moreover, by expanding their presence...

November 2010

AstraZeneca Reports Decline In Sales And Profits

Industry / United Kingdom BMI View: AstraZeneca's Q310 results reinforce our view that emerging markets will drive industry growth. The company's sales in Western Europe declined by 5.95% in Q310 while sales in the US dropped by...

October 2010

NICE To Be Sidelined In Assessing Medicine Cost Effectiveness

Industry / United Kingdom BMI View: The adoption of value-based pricing in place of the National Institute for Health and Clinical Excellence (NICE)'s cost-effectiveness calculations will improve the chances of innovative medicines...

October 2010